Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

DISEASE CHARACTERISTICS: Morphologically confirmed acute myeloid leukemia of 1 of the following subtypes: Acute myeloblastic leukemia (M0, M1, M2) Acute myelomonocytic leukemia (M4) Acute monocytic leukemia (M5) Acute erythroleukemia (M6) Acute megakaryocytic leukemia (M7) Must have 1 of the following karyotypic abnormalities at the time of diagnosis: Complex cytogenetic abnormalities (≥ 3 cytogenetic clones) Abnormalities of chromosome 5 [-5 or del(5q)] Abnormalities of the long (q) arm of chromosome 3, 9, 11, 20, or 21 Abnormalities of the short (p) arm of chromosome 17, monosomy 7, t(9;22), or t(6;9) (8) In morphologic first complete remission*, as evidenced by all of the following for ≥ 4 weeks before study entry: Absolute neutrophil count > 1,000/mm^3 Platelet count > 100,000/mm^3 Leukemic blasts not present in the peripheral blood Cellularity of bone marrow biopsy > 20% with maturation of all cell lines Less than 5% blasts by bone marrow biopsy No extramedullary leukemia, such as CNS or soft tissue involvement NOTE: *Reduced hemoglobin concentration or hematocrit has no bearing on remission status Haploidentical (3/6 or 4/6 antigen matched [A, B, and DR]) family donor available PATIENT CHARACTERISTICS: Age 18 to 59 Performance status ECOG 0-2 Life expectancy Not specified Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 2.0 mg/dL AST < 2 times upper limit of normal Renal Creatinine ≤ 1.5 mg/dL Cardiovascular Ejection fraction > 40% by MUGA or echocardiogram None of the following within the past 3 months: Myocardial infarction Significant congestive heart failure Significant cardiac arrhythmia Pulmonary FEV_1 and DLCO > 50% of predicted Immunologic HIV negative No active or unresolved infection No evidence of invasive fungal infection (e.g., positive blood or deep tissue cultures or stains) Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No organ damage No other medical problem that would preclude study participation No other currently active tumor that would likely interfere with study treatment or that would likely compromise the patient's morbidity or mortality PRIOR CONCURRENT THERAPY: Biologic therapy No concurrent routine use of filgrastim (G-CSF) or sargramostim (GM-CSF) to accelerate hematopoietic recovery post-transplantation Chemotherapy More than 4 weeks since prior chemotherapy Endocrine therapy Not specified Radiotherapy More than 4 weeks since prior radiotherapy Surgery Not specified